UNEEG medical A/S

UNEEG medical A/S is a Danish medical technology company based in Allerød Municipality, Denmark, founded in 2005. The company specialises in ultra long-term subcutaneous electroencephalography (EEG) monitoring, a technology that allows continuous recording of brain activity beneath the skin for years rather than the days or weeks typical of conventional EEG. Its flagship solution, the UNEEG EpiSight System, is designed to give healthcare professionals objective, longitudinal seizure and sleep data to help manage epilepsy, particularly for the roughly 40% of people with epilepsy whose seizures remain uncontrolled despite trying at least two anti-seizure medications. The company describes its vision as "catalyzing brain health therapy with real-world data" and its mission as using a remote patient monitoring platform to capture real-world longitudinal EEG data. These Big Data streams are intended to be transformed by stakeholders such as physicians and drug developers into actionable insights that personalise treatment and reduce uncontrolled seizures. UNEEG positions its technology as relevant not only to epilepsy management but also to drug development, digital biomarkers and neuromodulation, with stated ambitions to expand into areas such as sleep and diabetes. UNEEG medical operates with subsidiaries and cooperates with scientific and technology partners in Europe and the United States. Its clinical and regulatory milestones include EU MDR certification for the UNEEG SubQ implant in 2024, FDA Breakthrough Device Designation for the UNEEG EpiSight solution in 2024, and EU approval in 2025 for 3-year continuous use of the UNEEG SubQ implant. The company has accumulated a substantial real-world dataset, reporting more than 450,000 hours of real-world EEG, including 10,000 annotated seizures and 150,000 hours of sleep data as of 2026. It is a privately held, entrepreneurial medtech company led by CEO Martin Stenfeldt.

UNEEG medical A/S was founded in 2005 in Denmark. From its base in Allerød Municipality, the company set out to develop a new approach to electroencephalography (EEG) that would overcome the limitations of conventional, short-duration recordings. Its core innovation is ultra long-term subcutaneous EEG monitoring, in which a small implant placed under the skin continuously records brain activity for years, allowing electrographic seizures to be detected in patients' daily lives. Over more than two decades, UNEEG medical built a body of clinical evidence and a growing real-world dataset. By 2021 the company had initiated its first US patient in a pivotal multi-centre study for US approval of the 24/7 EEG SubQ solution, conducted at institutions including the University of Pennsylvania and Mayo Clinic. In 2022, UNEEG medical and King's College London were awarded £1.8 million in the i4i Challenge Awards Call from the National Institute for Health and Care Research (NIHR) in the UK to conduct a multicentre, observational cohort study of the 24/7 EEG SubQ solution. Also in 2022, the company launched its UNEEG MyConnect data-transfer solution, which for the first time automatically sent EEG data from the patient to the hospital. In 2023, UNEEG surpassed 100 implantations, with the data collected continuing to strengthen its seizure detection algorithms, improve sleep detection, and expand understanding of EEG activity in people living with epilepsy. The year 2024 was a landmark one: UNEEG achieved an EU MDR certificate for the UNEEG SubQ implant, launched the UNEEG EpiSight solution for subcutaneous, ultra long-term, wireless EEG recording, and was granted FDA Breakthrough Device Designation for the UNEEG EpiSight solution within monitoring and diagnostic of epilepsy. The company also won a Red Dot award for product design concept in the Medical Devices and Technology category in 2024. In 2025, an investor-sponsored study in Italy began exploring pediatric use, including the first child implanted with the device, and the 24/7 SubQ system received EU approval for 3-year continuous use of the UNEEG SubQ Implant. By 2026, UNEEG had accumulated more than 450,000 hours of real-world EEG, including 10,000 annotated seizures and 150,000 hours of sleep data. The company continues to cooperate with scientific and technology partners in Europe and the US and foresees expansion beyond epilepsy into areas such as sleep and diabetes.

• 2026

  UNEEG accumulated more than 450,000 hours of real-world EEG, including 10,000 annotated seizures and 150,000 hours of sleep data.

• 2025

  Investor-sponsored study in Italy begins exploring pediatric use, including first child implanted.

• 2025

  24/7 SubQ system receives EU approval for 3-year continuous use of UNEEG SubQ Implant.

• 2024

  EU MDR certificate achieved for the UNEEG SubQ implant.

• 2024

  Launch of UNEEG EpiSight for subcutaneous, ultra long-term, wireless EEG recording.

• 2024

  UNEEG EpiSight solution granted FDA Breakthrough Device Designation.

• 2024

  Winner of Red Dot award for product design concept in Medical Devices and Technology.

• 2023

  UNEEG surpassed 100 implantations.

• 2022

  UNEEG medical and King's College London awarded £1.8 million in NIHR i4i Challenge Awards for a multicentre observational cohort study.

• 2022

  UNEEG MyConnect data-transfer solution launched.

• 2021

  First US patient initiated in pivotal multi-centre study for US approval of 24/7 EEG SubQ solution.

• 2005

  UNEEG medical founded in Denmark.

Pioneer of ultra long-term subcutaneous EEG monitoring for epilepsy management and brain health, using real-world longitudinal data to personalise treatment and support drug development.

• UNEEG EpiSight System

  Breakthrough solution in epilepsy management enabling continuous, subcutaneous EEG recording for years.

• UNEEG SubQ Implant

  Subcutaneous implant for ultra long-term EEG recording, approved in the EU for 3-year continuous use.

• UNEEG EpiSight Analyzer

  Analysis platform with a sleep analysis module allowing healthcare professionals to correlate sleep and seizure data.

• UNEEG MyConnect

  Data-transfer solution that automatically sends EEG data from the patient to the hospital.

1. 1UNEEG medical ultra long-term EEG monitoringuneeg.com
2. 2UNEEG medical history over the past 20 yearsuneeg.com
3. 3UNEEG medical who are weuneeg.com
4. 4Our Management - UNEEG medicaluneeg.com
5. 5UNEEG medical A/S (Denmark) - Wikidatawikidata.org